CYTO - Altamira Therapeutics GAAP EPS of -CHF29.13 revenue of CHF0.31M May, 16 2023 07:39 AM Altamira Therapeutics Ltd. 2023-05-16 07:39:37 ET Altamira Therapeutics press release ( NASDAQ: CYTO ):FY GAAP EPS of -CHF29.13. Revenue of CHF0.31M (+416.7% Y/Y). For further details see: Altamira Therapeutics GAAP EPS of -CHF29.13, revenue of CHF0.31M